2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Gene Editing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Systems-Based Hematology, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3693 A tomo-TMLI–based conditioning strategy incorporating liposomal mitoxantrone and cyclophosphamide is associated with reduced severe toxicity after autologous stem cell transplantation for lymphoid malignancies

Zhuoxin Wen, Bin Xu2, Wei Jiang3, Yuling Wan4, Andie Fu5, Yi Zhu6, Shiyuan Zhang7, Fankai Meng8, Changchun Zhang9, Jia Wei, MD, PhD10, Donghua Zhang, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology11
1 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Department of Oncology, The Sixth Hospital of Wuhan, Wuhan, China
4 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 Department of Oncology, The Sixth Hospital of Wuhan, Wuhan, China
10 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background

BEAM remains the standard conditioning regimen for autologous stem cell transplantation (ASCT) in relapsed/refractory lymphoid malignancies; however, regimen-related toxicities, particularly severe oral mucositis, remain clinically significant and may delay recovery and subsequent therapies. Helical tomotherapy-based total marrow and lymphoid irradiation (TOMO-TMLI) enables selective irradiation of marrow and lymphoid tissues while limiting normal organ exposure.We evaluated the safety and early clinical outcomes of a TOMO-TMLI-based conditioning regimen incorporating liposomal mitoxantrone (Lipo-MIT) and cyclophosphamide (Cy) compared with standard BEAM conditioning.

Methods

We conducted a retrospective single-center comparative cohort study of consecutive patients with lymphoid malignancies undergoing ASCT. Patients receiving TOMO-TMLI/Lipo-MIT/Cy conditioning (n=15) were compared with contemporaneous patients receiving standard BEAM conditioning (n=27) during the same study period. Conditioning selection was based on institutional practice and physician discretion.TOMO-TMLI was delivered using helical tomotherapy on day −7, with site-specific dose prescriptions to marrow, CNS, and nodal targets. Lipo-MIT (20 mg/m² on day −6) and Cy (1.8 g/m² on days −5 and −4) were subsequently administered.The primary endpoint was the incidence of grade ≥3 non-hematologic toxicities according to CTCAE version 5.0. Secondary endpoints included neutrophil and platelet engraftment, grade ≥3 oral mucositis, infectious complications, hepatic complications including veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), transfusion requirements, and duration of hospitalization.

Results

Forty-two patients were included, with 15 receiving TOMO-TMLI/Lipo-MIT/Cy and 27 receiving BEAM conditioning. Baseline characteristics were generally balanced between groups, although this was a retrospective, non-randomized comparison.

The incidence of grade ≥3 non-hematologic toxicity was significantly lower in patients treated with TOMO-TMLI/Lipo-MIT/Cy, occurring in 2 of 15 patients (13.3%) compared with 13 of 27 patients (48.1%) receiving BEAM (P=0.024). Grade ≥3 oral mucositis was also reduced with TOMO-TMLI/Lipo-MIT/Cy, observed in 2 of 15 patients (13.3%) compared with 12 of 27 patients (44.4%) receiving BEAM (P=0.040).No cases of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) were observed in either group. Infectious complications were comparable between groups.

Hematopoietic recovery was comparable between groups. Median neutrophil engraftment occurred at day 13 in the TOMO-TMLI/Lipo-MIT/Cy group and day 14 in the BEAM group (P=0.60). Median platelet engraftment occurred at day 13 in the TOMO-TMLI/Lipo-MIT/Cy group and day 13.5 in the BEAM group (P=0.80). Infection rates, transfusion requirements, and duration of hospitalization were similar between groups.Day +100 disease response was evaluable in 39 patients. Complete response was achieved in 12 of 13 evaluable patients (92.3%) in the TOMO-TMLI/Lipo-MIT/Cy group and 23 of 26 evaluable patients (88.5%) in the BEAM group. Overall response rates were 92.3% in both groups.With a median follow-up of 22.6 months, survival outcomes were comparable between groups. The hazard ratio for overall survival was 0.91 (95% CI, 0.17–4.99; P=0.917), and the hazard ratio for progression-free survival was 0.91 (95% CI, 0.17–4.97; P=0.910). At 1 year, estimated overall survival was 86.7% in the TOMO-TMLI/Lipo-MIT/Cy group and 85.0% in the BEAM group, while estimated progression-free survival was 86.7% and 85.0%, respectively.

Conclusion

A TOMO-TMLI-based conditioning regimen incorporating Lipo-MIT and Cy was associated with reduced severe regimen-related toxicities while maintaining comparable hematopoietic recovery and early disease outcomes compared with BEAM. These findings support further prospective evaluation of TOMO-TMLI-based conditioning as a potential toxicity-sparing approach.

Donghua Zhang, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology: No relevant conflicts of interest to declare.